- Asymchem’s net income for 1Q stands at 282.0M Yuan, experiencing a decrease of 55% y/y
- The company’s revenue is reported as 1.40 billion yuan, witnessing a 38% decline y/y
- The firm has earned more prospective buyers with 22 buys, demonstrating investor confidence
- No investors are currently holding, denoting possible market fluctuations
- There have been 2 sells, indicating some investor uncertainty
- All these comparisons have been made using values presented in the company’s original disclosures
A look at Asymchem Laboratories Tianjin Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Asymchem Laboratories Tianjin shows a promising long-term outlook. With high scores in Value and Dividend, indicating strong financial health and potential for returns to investors. The company also scored well in Resilience, showcasing its ability to withstand market fluctuations. However, the Growth score was moderate, suggesting room for improvement in expansion strategies. Furthermore, the Momentum score was on the lower end, signifying potential challenges in maintaining a positive market trend. Overall, Asymchem Laboratories Tianjin, a pharmaceutical company that researches, produces, and sells chemicals and medicines globally, presents a solid foundation for investors to consider.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
